Our portfolio company Mekonos has formed an exciting new partnership with Neochromosome, Inc., (a wholly-owned subsidiary of Opentrons Labworks focused on the creation of genome-scale cell engineering solutions) to advance cell engineering for personalized cell therapies by building designer chromosomes as part of the next generation of cell therapy.
